Medtronic PLC $MDT Shares Acquired by W.H. Cornerstone Investments Inc.

W.H. Cornerstone Investments Inc. boosted its position in shares of Medtronic PLC (NYSE:MDT) by 44.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 17,643 shares of the medical technology company’s stock after buying an additional 5,390 shares during the period. Medtronic comprises 1.0% of W.H. Cornerstone Investments Inc.’s portfolio, making the stock its 23rd biggest holding. W.H. Cornerstone Investments Inc.’s holdings in Medtronic were worth $1,538,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in MDT. Gilbert & Cook Inc. raised its holdings in shares of Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after purchasing an additional 114 shares in the last quarter. Red Spruce Capital LLC lifted its holdings in Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after purchasing an additional 118 shares in the last quarter. Certior Financial Group LLC grew its holdings in Medtronic by 3.7% in the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after purchasing an additional 122 shares during the period. PrairieView Partners LLC increased its position in shares of Medtronic by 3.6% in the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock worth $324,000 after acquiring an additional 128 shares in the last quarter. Finally, Motco grew its stake in Medtronic by 27.0% during the 1st quarter. Motco now owns 635 shares of the medical technology company’s stock valued at $57,000 after purchasing an additional 135 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on MDT shares. Wells Fargo & Company boosted their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Citigroup raised their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $111.00 target price on shares of Medtronic in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $102.82.

Medtronic Stock Up 0.5%

MDT stock traded up $0.43 during trading on Thursday, hitting $96.24. 869,383 shares of the stock traded hands, compared to its average volume of 7,409,373. The stock has a market cap of $123.45 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The firm’s 50 day moving average is $94.31 and its two-hundred day moving average is $90.22.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Insider Transactions at Medtronic

In other Medtronic news, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.